Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy

Summary

Research Questions: 1. Does using dabigatran bridging result in consistent therapeutic anticoagulation? What percentage of patients will become subtherapeutic on warfarin once dabigatran is stopped? 2. What is the incidence of bleeding events with the use of dabigatran overlapped with warfarin for bridging? 3. What is the cost benefit of using dabigatran instead of dalteparin for bridging anticoagulation?

Timeline

Start

2013-03

Primary completion

2013-07

Completion

2013-09

Outcome

Outcome not reported

Stopped (Enrollment): “No patients recruited”

Drugs

Indications